Phase 3 ADHD Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must have completed the full treatment and follow-up period of the earlier related study (Trial 405-102-00112) without being asked to stop taking the study medication early.
- You must have followed the rules of the earlier study well, including taking the study medication as instructed.
Who may not be able to join:
- You cannot join if you are pregnant, breastfeeding, or if a pregnancy test at your first visit comes back positive.
- You cannot join if you have started, or if your doctor thinks you should start, any medications or therapies that are not allowed under this trial (for ADHD or related conditions) since the end of the previous study.
- You cannot join if your doctor has concerns about a significant risk of you harming yourself, or if you reported thoughts of suicide (on specific questions in a safety assessment) or any suicidal behaviour during the earlier study (confirm with trial site).
- You cannot join if you experienced any serious or severe side effects during the earlier study that were believed to be caused by the study medication.
- You cannot join if a urine test at your first visit shows a positive result for drugs or alcohol.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Nobuhito Sanada, Otsuka Pharmaceutical Co., Ltd.
Phone: +81-3-6361-7314
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Patients Experiencing Treatment-Emergent Adverse Events (TEAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.